A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Public ClinicalTrials.gov record NCT06196203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Study identification
- NCT ID
- NCT06196203
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Akeso
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- AK117 Drug
- Azacitidine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 6, 2024
- Primary completion
- Dec 31, 2025
- Completion
- May 31, 2026
- Last update posted
- Feb 10, 2025
2024 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Ronald Reagan Medical Center | Los Angeles | California | 90095 | Recruiting |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06510 | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | Recruiting |
| American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda) | Bethesda | Maryland | 20817 | Recruiting |
| Maryland Oncology-Columbia | Columbia | Maryland | 21044 | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | Recruiting |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx | New York | 10467 | Recruiting |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | Recruiting |
| Gabrail Cancer Center | Canton | Ohio | 44718 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Oncology Associates of Oregon | Eugene | Oregon | 97401 | Recruiting |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | Recruiting |
| UT Southwestern Medical Center | Dallas | Texas | 75390-9065 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06196203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06196203 live on ClinicalTrials.gov.